WIDEX Pure Sound Technology: New New Breakthrough Technology Reproduces Natural Sound in Hearing Aids

February 2, 2021

Widex PureSound technology, available for the first time in its new flagship WIDEX MOMENT™ hearing aids, features two distinct signal processing pathways — a “classic” version and a new ZeroDelay™ Accelerator pathway that dramatically changes how hearing aids sound.

“Sound quality and the ‘naturalness’ of sound remain among the most-cited reasons people don’t pursue hearing assistance, despite the great strides in hearing aid innovation made over the last decades,” said Widex Head of Audiology Lise Henningsen. “When hearing aids went digital, drastic improvements in noise reduction and advanced signal processing came at a price, but Widex has figured out how to overcome it.”

Taking an analog sound wave, converting it to a digital signal, processing it, then re-converting into a sound wave takes anywhere from 4 to 8 milliseconds. Studies have shown that a processing delay of that length can adversely affect sound quality, especially if processed sound and unprocessed sound mix in the ear canal of a hearing aid user, creating what is called a comb filter effect.

“When that happens, the perceived quality of the user’s own voice becomes tinny and artificial,” Henningsen said. “Environmental sounds come out distorted and unusual and, overall, the resulting sound becomes strenuous to listen to over time.”

The new Widex ZeroDelay Accelerator reduces the processing delay in WIDEX MOMENT hearing aids to below 0.5 milliseconds — a remarkable technological feat considering Widex already leads the industry with the lowest system delay through its “classic” processing pathway. The company’s unique, legacy time domain filter bank, 32kHz sampling rate, and 16kHz digital bandwidth create very high-fidelity sound across its family of hearing aids, with a processing delay under 3 milliseconds.

For the second, accelerated pathway in Widex PureSound-based hearing aids, signal processing is adapted to the ZeroDelay design to deliver the purest sound quality. Core functions, such as acoustics stability, adaptive gain control, and enhanced signal-to-noise ratio, continue to take priority, while others are modified for the faster ZeroDelay pathway. The two pathways — ZeroDelay and “classic” — exist side-by-side on the Widex PureSound platform. Depending on the needs of the wearer, a hearing care professional can program one or the other as the default mode. From there, the PureSound platform is adaptable to each user’s situation and preferred hearing experience.

“The wearer of hearing aids with the two distinct pathways can switch between them based on where they are and what they want to hear, thereby enjoying far greater sound quality and a more natural experience in most situations,” said Henningsen. Other information here.

SourceWIDEX

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”